Michael Raab G.'s most recent trade in Ardelyx Inc was a trade of 41,668 Common Stock done at an average price of $5.1 . Disclosure was reported to the exchange on July 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.06 per share. | 15 Jul 2026 | 41,668 | 1,678,366 (2%) | 0% | 5.1 | 210,923 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 15 Jul 2026 | 20,834 | 1,720,034 (2%) | 0% | 1.0 | 20,626 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2026 | 20,834 | 290,834 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.67 per share. | 15 Jun 2026 | 41,666 | 1,699,200 (2%) | 0% | 5.7 | 236,346 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 20,833 | 311,668 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 15 Jun 2026 | 20,833 | 1,740,866 (2%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.27 per share. | 21 May 2026 | 17,926 | 1,734,061 (2%) | 0% | 6.3 | 112,351 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.27 per share. | 21 May 2026 | 14,933 | 1,759,848 (2%) | 0% | 6.3 | 93,593 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.27 per share. | 21 May 2026 | 14,028 | 1,720,033 (2%) | 0% | 6.3 | 87,920 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.27 per share. | 21 May 2026 | 7,861 | 1,751,987 (2%) | 0% | 6.3 | 49,269 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.28 per share. | 15 May 2026 | 41,666 | 1,774,781 (2%) | 0% | 6.3 | 261,612 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 20,833 | 332,501 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 15 May 2026 | 20,833 | 1,816,447 (2%) | 0% | 1.0 | 20,625 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 14.50 per share. | 27 Apr 2026 | 115,857 | 0 (0%) | 0% | 14.5 | 1,679,927 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 74,872 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 45,423 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 42,467 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 36,111 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 30,474 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 20,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 19,473 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 18,574 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 16,236 | 0 | - | - | Stock Options (right to buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.29 per share. | 15 Apr 2026 | 41,668 | 1,795,614 (2%) | 0% | 6.3 | 261,954 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2026 | 20,834 | 353,334 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 15 Apr 2026 | 20,834 | 1,837,282 (2%) | 0% | 1.0 | 20,626 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.84 per share. | 16 Mar 2026 | 41,666 | 1,816,448 (2%) | 0% | 5.8 | 243,329 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 16 Mar 2026 | 20,833 | 1,856,986 (2%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 20,833 | 374,168 | - | - | Stock Option (Right to Buy) | |
| Tempest Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2026 | 1,230 | 1,230 | - | - | Stock Option (right to buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2026 | 669,330 | 669,330 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2026 | 446,220 | 1,902,968 (2%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.54 per share. | 21 Nov 2025 | 46,887 | 1,455,363 (2%) | 0% | 5.5 | 259,609 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.93 per share. | 21 Aug 2025 | 45,687 | 1,502,250 (2%) | 0% | 5.9 | 271,002 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 74,872 | 74,872 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 20,414 | 115,857 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.08 per share. | 20 May 2025 | 46,817 | 1,547,937 (2%) | 0% | 4.1 | 191,079 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.25 per share. | 02 May 2025 | 41,666 | 1,594,754 (2%) | 0% | 4.3 | 177,168 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 02 May 2025 | 20,833 | 1,636,420 (2%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 20,833 | 415,834 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.59 per share. | 04 Apr 2025 | 41,666 | 1,615,587 (2%) | 0% | 4.6 | 191,151 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 04 Apr 2025 | 20,833 | 1,657,253 (2%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2025 | 20,833 | 436,667 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.36 per share. | 07 Mar 2025 | 41,668 | 1,635,138 (2%) | 0% | 5.4 | 223,199 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 07 Mar 2025 | 20,834 | 1,676,806 (2%) | 0% | 1.0 | 20,626 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 20,834 | 457,500 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 855,326 | 855,326 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 570,217 | 1,655,972 (2%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.62 per share. | 20 Feb 2025 | 22,964 | 1,085,755 (1%) | 0% | 5.6 | 129,124 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.36 per share. | 31 Jan 2025 | 41,666 | 1,108,719 (1%) | 0% | 5.4 | 223,355 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 20,833 | 478,334 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 31 Jan 2025 | 20,833 | 1,150,385 (1%) | 0% | 1.0 | 20,625 | Common Stock |
| Ardelyx Inc | Raab Michael G. | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.26 per share. | 10 Dec 2024 | 25,000 | 1,150,385 (1%) | 0% | 5.3 | 131,620 | Common Stock |
| Ardelyx Inc | Raab Michael G. | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 25,000 | 520,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 10 Dec 2024 | 25,000 | 1,175,385 (1%) | 0% | 1.0 | 24,750 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.38 per share. | 25 Nov 2024 | 25,000 | 1,150,385 (1%) | 0% | 5.4 | 134,483 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.79 per share. | 20 Nov 2024 | 31,980 | 1,175,385 (1%) | 0% | 4.8 | 153,328 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 4.90 per share. | 11 Nov 2024 | 2,743 | 1,207,365 (1%) | 0% | 4.9 | 13,441 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 28 Oct 2024 | 25,000 | 1,235,108 (1%) | 0% | 1.0 | 24,750 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2024 | 25,000 | 545,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.91 per share. | 28 Oct 2024 | 25,000 | 1,210,108 (1%) | 0% | 5.9 | 147,740 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 11 Oct 2024 | 7,500 | 1,210,108 (1%) | 0% | 6.0 | 45,075 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 26 Sep 2024 | 3,000 | 1,217,608 (1%) | 0% | 6.1 | 18,210 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 11 Sep 2024 | 35,000 | 1,255,608 (1%) | 0% | 1.0 | 34,650 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 35,000 | 570,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.61 per share. | 11 Sep 2024 | 35,000 | 1,220,608 (1%) | 0% | 5.6 | 196,399 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.22 per share. | 27 Aug 2024 | 7,500 | 1,219,509 (1%) | 0% | 6.2 | 46,635 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.86 per share. | 20 Aug 2024 | 32,225 | 1,227,009 (1%) | 0% | 5.9 | 188,848 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.71 per share. | 12 Aug 2024 | 1,229 | 1,259,234 (1%) | 0% | 5.7 | 7,018 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 29 Jul 2024 | 30,000 | 1,290,463 (1%) | 0% | 1.0 | 29,700 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jul 2024 | 30,000 | 605,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.64 per share. | 29 Jul 2024 | 30,000 | 1,260,463 (1%) | 0% | 5.6 | 169,314 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 5.97 per share. | 15 Jul 2024 | 7,500 | 1,260,463 (1%) | 0% | 6.0 | 44,768 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.59 per share. | 28 Jun 2024 | 2,310 | 1,267,963 (1%) | 0% | 6.6 | 15,223 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.65 per share. | 13 Jun 2024 | 35,000 | 1,270,273 (1%) | 0% | 6.6 | 232,743 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 665,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 13 Jun 2024 | 35,000 | 1,305,273 (1%) | 0% | 1.0 | 34,650 | Common Stock |
| Tempest Therapeutics Inc | Michael G. Raab | Director | 13 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | ||
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 42,467 | 42,467 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 11,847 | 95,443 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.72 per share. | 29 May 2024 | 7,500 | 1,270,273 (1%) | 0% | 6.7 | 50,390 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.81 per share. | 21 May 2024 | 31,484 | 1,277,773 (1%) | 0% | 7.8 | 245,922 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.99 per share. | 14 May 2024 | 3,000 | 1,307,933 (1%) | 0% | 8.0 | 23,970 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.99 per share. | 29 Apr 2024 | 30,000 | 1,340,933 (2%) | 0% | 1.0 | 29,700 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2024 | 30,000 | 670,000 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 6.40 per share. | 29 Apr 2024 | 30,000 | 1,310,933 (1%) | 0% | 6.4 | 192,057 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.06 per share. | 15 Apr 2024 | 7,500 | 1,310,933 (1%) | 0% | 7.1 | 52,924 | Common Stock |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.31 per share. | 01 Apr 2024 | 1,518 | 1,318,433 (2%) | 0% | 7.3 | 11,097 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.80 per share. | 05 Mar 2024 | 15,000 | 83,596 (0%) | 0% | 2.8 | 42,000 | Common Stock |
| Ardelyx Inc | Michael Raab G. | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 8.75 per share. | 20 Feb 2024 | 22,917 | 1,319,951 (2%) | 0% | 8.7 | 200,439 | Common Stock |
| Ardelyx Inc | Michael Raab G. | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 605,904 | 605,904 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 475,000 | 1,342,868 (2%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.55 per share. | 21 Aug 2023 | 11,419 | 876,236 (1%) | 0% | 3.6 | 40,558 | Common Stock |
| Tempest Therapeutics Inc | Michael G. Raab | Director | 15 Jun 2023 | 8,200 | 8,200 | - | - | Stock Option (right to buy) | ||
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,474 | 30,474 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 8,584 | 68,596 (0%) | 0% | 0 | Common Stock | |
| Ardelyx Inc | Michael G. Raab | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 3.65 per share. | 23 May 2023 | 11,357 | 887,655 (1%) | 0% | 3.7 | 41,489 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.32 per share. | 17 Mar 2023 | 15,000 | 64,420 (0%) | 0% | 3.3 | 49,800 | Common Stock |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2023 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Michael G. Raab | Director | Sale of securities on an exchange or to another person at price $ 11.33 per share. | 17 Mar 2023 | 4,408 | 60,012 (0%) | 0% | 11.3 | 49,943 | Common Stock |